Siponimod

Introduction Overview

Generic Name

siponimod

Brand Name

Mayzent

Dosage Form

tablet

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Siponimod is rapidly absorbed following oral administration with an approximate bioavailability of 84%. Peak plasma concentrations are typically achieved within 4 to 6 hours post-dose. Food intake does not significantly affect the absorption of siponimod, making dosing with or without food clinically acceptable. The drug exhibits linear pharmacokinetics over the therapeutic dose range, allowing predictable dose-concentration relationships. Extensive first-pass metabolism is observed but does not limit systemic availability significantly.

Distribution:
Siponimod exhibits a large volume of distribution, estimated to be approximately 1243 L, indicating extensive tissue distribution. It is highly plasma protein-bound (~97%), primarily to albumin. The ability of siponimod to cross the blood-brain barrier enables it to exert its pharmacological effects on central nervous system (CNS) immune cells. Siponimod’s distribution into lymphoid tissues and CNS is essential for its immunomodulatory activity.

Metabolism:
Siponimod is metabolized primarily in the liver via cytochrome P450 isoenzymes, especially CYP2C9 and CYP3A4. Genotypic variations in CYP2C9 significantly influence siponimod metabolism and clearance, necessitating genotype testing before initiation. Metabolism results in multiple inactive metabolites, and the parent compound is the major circulating moiety. The metabolic pathway’s reliance on polymorphic enzymes demands consideration of potential drug interactions and personalized dosing.

Elimination:
The elimination half-life of siponimod is approximately 30 hours, supporting once-daily dosing. It is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 5% of total clearance. The metabolites and unchanged drug are excreted in both urine and feces. Steady-state is typically reached after 6 days of once-daily dosing. Due to its pharmacokinetics, dose interruptions require careful re-initiation with close monitoring to avoid adverse cardiac effects.

Dosage Forms

Available Dosage Forms:
Mayzent is available exclusively as oral tablets. The marketed tablet strengths include 0.25 mg, 1 mg, and 2 mg. Each strength is characterized by specific film coatings containing iron oxides for color differentiation and other inactive ingredients including colloidal silicon dioxide, crospovidone, glyceryl dibehenate, and lactose monohydrate among others.

Dosages for Adults and Adolescents:
The dosing regimen for Mayzent is genotype-guided based on CYP2C9 allelic variants. For patients with CYP2C9 genotypes *1/*1, *1/*2, or *2/*2, titration begins at 0.25 mg orally once daily on days 1 and 2, increasing gradually to a maintenance dose of 2 mg once daily starting on day 6 using a specialized starter pack. For patients with CYP2C9 *1/*3 or *2/*3 genotypes, titration follows a similar approach but maintains a lower maintenance dose of 1 mg once daily starting on day 5, and the starter pack is not used. If doses are missed for more than 24 hours during titration, the titration must be restarted from day 1. After interruption of therapy for 4 or more consecutive days, re-initiation follows the full titration regimen with medical monitoring.

Specific Patient Populations:
Dosing adjustment is critical based on the patient's CYP2C9 genotype to avoid excessive drug exposure and related cardiac adverse effects. Close monitoring for bradycardia and conduction abnormalities is recommended during initial dosing, especially in patients with pre-existing cardiac conditions such as sinus bradycardia or atrioventricular block. The maintenance dosing is uniform after genotype-guided titration. No dose adjustment is generally necessary for elderly patients; however, caution is warranted in hepatic impairment due to metabolism pathways. Safety and efficacy in pediatric populations under 18 years of age have not been established. Renal impairment does not necessitate dose adjustments since renal elimination is minimal.

Mechanism Of Action

Siponimod, the active ingredient in Mayzent, is a selective modulator of sphingosine 1-phosphate (S1P) receptor subtypes 1 and 5. It acts by binding to these G protein-coupled receptors located on the surface of lymphocytes and vascular endothelial cells. Upon activation, siponimod induces receptor internalization and functional antagonism, which results in the sequestration of lymphocytes in lymph nodes. This prevents autoreactive lymphocytes from migrating into the central nervous system, thereby reducing neuroinflammation associated with multiple sclerosis (MS).

On a cellular level, siponimod’s modulation of S1P1 receptors limits the egress of pathogenic T and B lymphocytes from lymphoid tissues without broadly suppressing the immune system. This selective immunosuppression reduces demyelination and axonal damage, key pathological features of relapsing forms of MS. Additionally, siponimod’s activity on S1P5 receptors present on oligodendrocytes and CNS cells may promote remyelination and neuroprotection, although these effects require further clinical validation.

Biochemically, siponimod’s interaction with S1P receptors alters downstream signaling pathways involving cyclic AMP, calcium mobilization, and mitogen-activated protein kinases, culminating in altered cell trafficking and survival. The result is a reduction in inflammatory cell infiltration into the CNS, stabilization of the blood-brain barrier, and mitigation of neurodegeneration.

Clinically, siponimod’s mechanism differentiates it from non-selective S1P modulators by limiting cardiovascular adverse effects associated with S1P3 receptor activation. Research including the pivotal EXPAND trial demonstrated that siponimod effectively delays sustained disability progression in patients with secondary progressive MS, thus providing a disease-modifying option for this challenging patient population. The mechanism has parallels with fingolimod but with improved receptor subtype selectivity, enhancing its therapeutic index.

Pharmacological Actions

Selective modulation of sphingosine 1-phosphate (S1P) receptor subtypes 1 and 5.
Functional antagonism of S1P1 receptor results in lymphocyte sequestration in lymph nodes.
Reduction of autoreactive lymphocyte infiltration into the central nervous system.
Immunosuppressive effects that reduce neuroinflammation associated with multiple sclerosis.
Potential neuroprotective effects through activity on oligodendrocyte S1P5 receptors.
Limitation of lymphocyte egress without broad immune suppression.
Stabilization of the blood-brain barrier integrity.
Reduction in demyelination and axonal damage in MS patients.
Improved cardiovascular safety profile due to selective receptor targeting.
Dose-dependent bradycardia and conduction effects reflecting cardiac S1P receptor modulation.
Decrease of inflammatory cytokine release from immune cells.
Modulation of downstream signaling cascades involved in cell trafficking and survival.

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis including relapsing-remitting MS.
Management of active secondary progressive multiple sclerosis in adults.
Prevention of relapse episodes and slowing disability progression in MS.
Applicable to clinically isolated syndrome with risk of developing MS.
Reduction of neuroinflammatory activity contributing to MS pathogenesis.
Use in genotype-tested patients to optimize safety and efficacy.
Alternative disease-modifying therapy for patients intolerant to other agents.
Treatment aimed at improving quality of life by delaying neurological deterioration.
Utility in patients with contraindications to other immunomodulatory therapies.
Potential option for patients with inadequate response to first-line MS therapies.

Side Or Adverse Effects

Headache, frequently reported during therapy.
Increased blood pressure requiring monitoring.
Abnormal liver function tests indicating hepatic effect.
Bradycardia and slow or irregular heartbeats, especially at treatment initiation.
Vision disturbances including macular edema and increased photosensitivity.
Allergic reactions with symptoms such as hives and facial swelling.
Signs of serious infections, including fever, chills, and meningitis symptoms.
Seizures and changes in mental status including confusion.
Oral, genital, or anal sores potentially due to viral reactivation.
Skin changes and unusual moles suggestive of melanoma risk.
Shortness of breath related to pulmonary side effects.
Gastrointestinal symptoms including nausea and vomiting.
Jaundice and other symptoms related to liver dysfunction.
Progressive multifocal leukoencephalopathy (PML) risk with long-term use.
Potential worsening of multiple sclerosis symptoms upon abrupt discontinuation.

Precautions

Genotype testing (CYP2C9) required before therapy initiation to guide dosing and avoid toxicity.
Careful cardiac evaluation prior to treatment due to risk of bradycardia and heart block.
First dose should be administered in a monitored medical setting with ECG and vital sign monitoring.
Avoid interruption or missed doses without physician guidance due to risk of symptom rebound.
Regular monitoring of liver function tests during treatment.
Periodic ophthalmologic examinations to detect macular edema, especially in diabetic or uveitis patients.
Patient education to recognize signs and symptoms of infection promptly.
Hydration and blood pressure monitoring advised given hypertensive potential.
Avoidance of live vaccines during therapy and for at least four weeks after discontinuation.
Pregnancy prevention recommended; effective contraception during and for 10 days after treatment.
Breastfeeding safety not established; weigh risks and benefits.
Avoid concomitant use of heart rhythm-altering medications without close monitoring.
Monitor for skin changes and conduct dermatologic evaluations for melanoma screening.
Caution in patients with a history of respiratory disorders such as asthma or sleep apnea.
Increased infection risk warrants vaccination history assessment and immunization updates before therapy.

Warnings

Contraindicated in patients with serious heart conditions including sick sinus syndrome and advanced AV block without pacemaker.
First-dose bradycardia necessitates administration under medical supervision.
Risk of serious and potentially fatal infections due to immune system suppression.
Increased risk of macular edema, with vision changes occurring 1–4 months after treatment initiation.
Potential for severe hepatic injury; monitor liver enzymes regularly.
May cause progressive multifocal leukoencephalopathy (PML) with longer therapy durations over 18 months.
Abrupt discontinuation can cause rebound MS disease activity and worsening symptoms.
Live vaccines contraindicated during treatment and within 4 weeks after cessation.
May increase blood pressure requiring regular monitoring.
Can cause fetal harm; use effective contraception and avoid during pregnancy.
Requires genotype testing to prevent overdose and cardiac toxicity.
Concomitant use with certain antiarrhythmic agents may exacerbate cardiac risks.
Monitor closely if patient has history of stroke, myocardial infarction, or heart failure.
Patients with diabetes or uveitis at heightened risk for ocular adverse effects.
Risk of skin cancer including melanoma necessitates ongoing dermatological vigilance.

Contraindication

Known hypersensitivity to siponimod or any component of the formulation.
CYP2C9 genotype *3/*3 — contraindicated due to increased exposure and toxicity risk.
Second or third-degree atrioventricular (AV) block without pacemaker.
Sinus node dysfunction or sick sinus syndrome without pacemaker.
Recent (within 6 months) history of myocardial infarction, unstable angina, stroke, TIA, heart failure, or other serious cardiac conditions.
Severe liver impairment due to altered metabolism.
Use with certain antiarrhythmic medications that prolong AV conduction without appropriate monitoring.
Active serious infections, including immunosuppressive states not controlled by therapy.
Concurrent use of live attenuated vaccines.
Pregnancy given potential teratogenicity and fetal risk.
Severe hypersensitivity reactions including anaphylaxis to related compounds.
Patients unable to comply with first-dose monitoring or follow-up requirements.
Unstable angina or uncontrolled hypertension.
Known severe bradyarrhythmias.
Patients with conditions predisposing to macular edema without appropriate ophthalmic management.

Drug Interactions

CYP2C9 inhibitors or inducers can significantly alter siponimod plasma levels, necessitating dose adjustments.
Co-administration with CYP3A4 inhibitors or inducers may affect siponimod metabolism and efficacy.
Use with antiarrhythmic drugs such as amiodarone, disopyramide, dofetilide, dronedarone, flecainide, ibutilide, procainamide, propafenone, quinidine, or sotalol increases risk of cardiac conduction abnormalities.
Potential additive immunosuppressive effects with other immunomodulators, cancer chemotherapy, or corticosteroids.
Concurrent use with live vaccines may reduce vaccine efficacy and increase infection risk.
Medications that affect heart rate or rhythm may exacerbate siponimod-induced bradycardia.
Drugs affecting lymphocyte trafficking or immune cell function may have synergistic or antagonistic effects.
Herbal supplements and over-the-counter products affecting CYP enzymes may interact with siponimod.
Drugs altering blood pressure may compound hypertensive or hypotensive effects.
Interactions with antidepressants or antipsychotics causing QT prolongation should be used with caution.
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase siponimod concentrations.
Inducers of CYP enzymes (e.g., rifampin) may reduce siponimod efficacy by lowering plasma levels.
Immunization with live vaccines during or shortly after treatment should be avoided due to risk of uncontrolled infections.
Drugs with narrow therapeutic indices that affect cardiac conduction require close monitoring when combined.
Potential interaction with antimalarial and HIV medications necessitating monitoring and dose adjustments.

Preparations Of The Drug

Film-coated oral tablets in strengths of 0.25 mg, 1 mg, and 2 mg.
Tablets contain inactive ingredients such as colloidal silicon dioxide, crospovidone, glyceryl dibehenate, lactose monohydrate, microcrystalline cellulose.
Tablet coatings include colorants like black, red, and yellow iron oxides depending on strength.
Tablets designed to be swallowed whole; crushing or splitting is not recommended.
Packaged in starter packs for titration dosing specific to patient genotype.
Stored unopened in refrigerated conditions; do not freeze.
Once opened, tablets are stable at room temperature away from moisture and heat for up to 3 months.
Manufactured and distributed by Novartis Pharmaceuticals Corporation.
Available through prescription only with genotype testing required before dispense.
Comes with patient medication guides including monitoring and administration instructions.
Supplied with detailed dosing schedules intrinsic to titration protocols.
Non-hazardous handling with no special protective equipment required.
Packaging includes safety caps and clear labeling for differentiated dosage strengths.